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Here, we present the results of two genome-wide scans in two diverse populations in which a consistent use of recently introduced
migraine-phenotyping methods detects and replicates a locus on 10q22-q23, with an additional independent replication. No genetic
variants have been convincingly established in migraine, and although several loci have been reported, none of them has been consis-
tently replicated. We employed the three knownmigraine-phenotyping methods (clinical end diagnosis, latent-class analysis, and trait-
component analysis) with robust multiple testing correction in a large sample set of 1675 individuals from 210 migraine families from
Finland and Australia. Genome-wide multipoint linkage analysis that used the Kong and Cox exponential model in Finns detected a
locus on 10q22-q23 with highly signiﬁcant evidence of linkage (LOD 7.68 at 103 cM in female-speciﬁc analysis). The Australian sample
showed a LOD score of 3.50 at the same locus (100 cM), as did the independent Finnish replication study (LOD score 2.41, at 102 cM). In
addition, four previously reported loci on 8q21, 14q21, 18q12, and Xp21 were also replicated. A shared-segment analysis of 10q22-q23
linked Finnish families identiﬁed a 1.6-9.5 cM segment, centered on 101 cM, which shows in-family homology in 95% of affected Finns.
This region was further studied with 1323 SNPs. Although no signiﬁcant association was observed, four regions warranting follow-up
studies were identiﬁed. These results support the use of symptomology-based phenotyping in migraine and suggest that the 10q22-
q23 locus probably contains one or more migraine susceptibility variants.Introduction
Migraine (MIM 157300) is the most common cause of
chronic episodic severe headache. It affects some 15% of
the adult population and has a well-established genetic
component1–4 on the basis of family and twin studies. It
is more prevalent among women, with a ratio of roughly
one male to every three female migraineurs.1 Migraine is
the most common neurological cause of a doctor visit
and places a heavy ﬁnancial, social, and psychological bur-
den on a signiﬁcant part of the general population. The es-
timated annual cost of migraine in Europe is V27 billion.5
Although evidence from family studies and twin studies
have demonstrated the contribution of genetic factors to
migraine susceptibility,3,6,7 identiﬁcation of speciﬁc genetic
variants for common forms of migraine has not been forth-
coming. No variants predisposing to common forms of mi-
graine have been convincingly established, and no whole-
genome association (WGA) studies have been reported for
any headache disorders to date. Genome-wide linkage stud-
ies have pointed to several loci in both migraine with and
without aura.8–15 Unfortunately, so far there has been littleThe Amconcordance between linkage reports because most studies
have identiﬁeda locusor two,whichhavenotbeenconvinc-
ingly replicated in other studies. Applying ﬁndings from
other complex disorders suggests that the lack of progress
in gene identiﬁcation may be attributable to etiologic or
phenotypic heterogeneity, gene-environment interaction,
or epistasis. Another possible reason is genetic (locus) het-
erogeneity, in which only a subset of pedigrees segregates
markers linked to a particular risk locus. Then, even if the
study sample consists of a large number of families, individ-
ual large families within the sample carrying rare, relatively
high-impact gene variations predisposing to migraine can
be overly represented in the linkage signal. This would ex-
plain someof the difﬁcultieswith replication, andbetter un-
derstanding of how to account for these factors would help
in targeting future studies as well as help in interpreting re-
sults fromwhole-genomeassociationstudies. Finally,wehy-
pothesize that one of the reasons behind this inconsistency
might be related to the difﬁculty of phenotyping headache
disorders, causing heterogeneity in sample ascertainment.
One of the major impediments to gene identiﬁcation of
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a presumptive diagnosis of migraine can be made. A
migraine diagnosis is based on fulﬁllment of symptom
criteria formulated by the International Headache Society
(IHS).16,17 The criteria deﬁne two main subtypes of
migraine, migraine with aura (MA) and migraine without
aura (MO), which together account for a majority of all
migraine. Most studies performed so far have used the
migraine end diagnosis as the primary phenotype, i.e., by
considering only patients with either MA or MO diagnosis
as affected in analysis. Although the IHS classiﬁcationworks
well and is fundamental in clinical practice, itmaynot be an
optimal strategy for uncovering underlying genetic mecha-
nisms andpathways contributing to the disease. The second
edition of the IHS classiﬁcation17 introduced the same basic
symptom criteria (see Table 1) for MO and typical aura with
migraine headache (a major subgroup of MA). This, com-
bined with studies suggesting migraine with and without
auraaremanifestationsof thesameunderlyingdisorder,18,19
have led to joint genetic analysis of patients from both diag-
nosis groups. This, in turn, gave rise to the idea of concen-
trating on one or few cardinal migraine symptoms, which
might better reﬂect the underlying pathophysiology.
Two alternative analytic strategies, one utilizing latent
classes,18 the other examining trait components,11 have
recently been developed for use in genetic studies of
migraine. In the latent-class analysis (LCA) approach, indi-
viduals are classiﬁed into empirically derived groups on
the basis of patterns of IHS symptom clustering observed
in a large Australian twin sample.18 Although considerably
more individuals were classiﬁed as being affected with ‘‘mi-
grainousheadache’’ viaLCA(prevalence36%versus15%for
clinically determined migraine), additional studies in Aus-
tralian18 and Dutch20 twin populations have shown that
the LCA classiﬁcation is able to demonstrate linkage to
loci undetectable with only the end diagnosis. An alternate
strategy is the trait-component analysis (TCA) approach,
which takes direct advantage of the available clinical infor-
Table 1. Diagnostic Criteria for Migraine without Aura and
for the Headache Associated with Typical Aura with Migraine
Headache According to the International Classification
of Headache Disorders, Second Edition
1.1. Migraine without Auraa
A. At least five attacks fulfilling criteria B–D
B. Headache attacks lasting 4–72 hr (untreated or unsuccessfully
treated)
C. Headache has at least two of the following characteristics:
1.Unilateral location
2.Pulsating quality
3.Moderate or severe intensity (inhibits or prohibits daily activities)
4.Aggravation by walking stairs or similar routine physical activity
D. During headache, at least one of the following:
1.Nausea and / or vomiting
2.Photophobia and phonophobia
E. [Exclusion of secondary causes of headache]
a For typical aura with migraine headache (1.2.1): ‘‘Headache fulfilling
criteria B–D for 1.1 Migraine without aura begins during the aura or follows
aura within 60 min.’’1052 The American Journal of Human Genetics 82, 1051–1063, Maymation in the IHS symptom data in order to classify the
patients into groups. This approach has the advantage of
reﬂecting known variables obtained directly from patients
with no intervening hypotheses about latent structure and
relationships of the traits. It is also simple to implement
from patient questionnaires or interviews and has proved
to be successful in demonstrating linkage to loci undetect-
able with traditionalmethods in a previous Finnish study.11
Encouraged by our previous results with these alternative
phenotyping strategies and their potential to facilitate
data integration from different phenotyping schemes, we
genotyped and analyzed two new, independent genome-
wide linkage scans from Finland and Australia. The samples
are of roughly equal size but have differences in their ascer-
tainment strategies and pedigree structures, allowing us to
test the phenotyping methods in a variety of conditions.
Further, the special population history of Finns provides
an advantage to potential restriction of any linked locus
through extended haplotype sharing.
Material and Methods
Patients
The Finnish study sample for the genome-wide scan consisted of
690 migraine patients and their relatives (407 women and 283
men) in 58 independent, multigenerational families. The Austra-
lian sample consisted of 661 individuals (420 women and 241
men) in 125 independent nuclear families. The Finnish replication
sample consisted of 324 migraine patients (202 women and 122
men) in 27 independent, multigenerational families. In total, we
studied 1675 individuals from 210 independent families. All par-
ticipants gave informed consent, and approval to conduct the
research was obtained from the Helsinki University Central Hospi-
tal Ethics Committee for the Finnish study and from the Queens-
land Institute of Medical Research (QIMR) Human Research Ethics
Committee and the Australian Twin Registry for the Australian
study. For the follow-up association study, two study samples
from the Finnish population were used. The ﬁrst study sample
consisted of 39 unrelated trios with discordant parents selected
so that both the affected parent and an affected offspring carry
the family-speciﬁc segregating ‘‘risk haplotype’’ and that the unaf-
fected parent did not. The case-control set contained 256 unre-
lated MA cases selected from the Finnish patient collection and
230 controls from a Helsinki-based-population control sample.
Diagnoses and Phenotypes
TheFinnish familieswere selected froma large Finnishmigrainepa-
tient collection, ascertained from neurology clinics nation wide
during the last 15 years. The patients have been collected from fam-
ilieswith threeormoreaffectedmembers fulﬁllingmigrainecriteria
upon admission. Data on IHS attack symptoms as well as other
clinical features were collectedwith the validated FinnishMigraine
Speciﬁc Questionnaire for Family Studies (FMSQFS)
21 and by a neu-
rologist’s examination of index patients. The same neurologist
(M.K.) diagnosed all Finnish patients. The replication sample con-
sists of large families selected fromthe samepatient collection,with
a preference for more severe migraine patients, including those
with hemiparesis symptoms, because of ﬁndings in the Finnish
genome-wide sample.2008
The Australian families were selected from two population-
based twin cohorts, one of nuclear families of twins born between
1902 and 196422 and one of twins born between 1964 and 1971,23
with an overall prevalence of 15.3% of IHS migraine without aura.
The included pedigrees were selected on the basis of having at
least one pair of siblings affected for the common LCA-derived
‘‘migrainous headache’’ phenotype (prevalence of 36%18) and
then prioritized on the maximum number of available siblings,
irrespective of affection status. Data on IHS attack symptoms16,17
were gathered with an extensive semistructured telephone inter-
view that included diagnostic questions for migraine (Australian
questionnaires for the older and younger cohorts, see Web
Resources), developed by an experienced migraine researcher
(K.R.M.).24 Using a similar screening approach, Stewart et al.25
obtained a 92.6% positive predictive value of their telephone in-
terview diagnosis compared with their clinical examination. For
the younger cohort, data for two IHS diagnostic variables (Table 1),
nausea and vomiting (ICHD-II code: 1.1.D.1), were recorded
together. For the older cohort, data on three variables, pain inten-
sity (1.1.C.3), typical attack length (1.1.B), and whether patients
have had at least ﬁve attacks during lifetime (1.1.A), were unavail-
able, but symptom patterns of the younger cohort were used to
extrapolate those phenotypes for the older cohort. Data on
whether an individual’s headachewas aggravated by walking stairs
or similar routine physical activity (1.1.C.4) were missing for both
cohorts, and thus that trait was excluded from the study. We used
an answer to a visual aura-speciﬁc question to determine the MA
end diagnosis.
Table 2. Distribution of Migraine Diagnoses within









n of Total n of Total n of Total
Pure MAa 169 24% 44 14% 191 24%
Pure MO 79 11% 35 11% 78 10%
Unclassified MAb 89 13% 33 10%
Mixed migrainec 110 16% 78 24%
Equivalent migraine 7 1% 2 1%
Headache 26 4% 11 3%
No headache 169 24% 61 19% 230 28%
Possible migrained 27 4% 18 6%
Unknown 19 3% 42 13% 305 38%
MA end diagnosis 368 53% 155 48% 191 24%
Total 690 100% 324 100% 804 100%
Note the Australian symptom data do not allow the strict separation of
migraine with aura patients into unclassified MA, mixed migraine, and
pure migraine with aura subgroups.
a Pure MA refers to patients with all attacks fulfilling IHS criteria for
migraine with aura.
b Unclassified MA refers to an additional, non-IHS diagnosis group for
patients that cannot be grouped into any of the defined IHS categories.
Patients in this category suffer from attacks in which clearly aural features
are present but not in a form recognized by the current diagnostic criteria.
c Mixed migraine refers to a patient group in which attacks both with and
without aura are commonly present.
d Possible migraine refers to a patient group with episodic headache with
some migrainous features, who may or may not fulfill one of the probable
migraine (1.6) diagnoses of the IHS criteria but miss required aspects of
migraine with or without aura.The AmThree different phenotype groups were prepared. ‘‘MA end diag-
nosis’’ covers all migraine with aura patients and includes individ-
uals from diagnosis groups ‘‘pure MA,’’ ‘‘unclassiﬁed MA,’’ and
‘‘mixed migraine’’ as affected (see Table 2 for deﬁnitions). Table 2
details the diagnosis distributionwithin the study samples, includ-
ing a detailed diagnosis breakdown for the two Finnish study sam-
ples, in which the larger amount of available clinical information
and expertise allows for a higher diagnostic speciﬁcity for the clin-
ical diagnosis. The Australian study questionnaire has fewer
migraine-speciﬁc questions and is designed to identify migraine
with high sensitivity but does not allow for distinguishing be-
tween different subtypes of MA. The latent-class deﬁnitions were
estimated from each patients’ symptom distribution with the
same algorithm as in the original LCA study.18 In brief, of the
four latent cluster groups in LCA (termed CL0, CL1, CL2, and
CL3), all individuals satisfying the IHS MA or MO diagnostic crite-
ria are encompassed by groups CL2 and CL3, and the combination
of these two groups will be referred to as ‘‘LCA migrainous head-
ache.’’ Group CL3, which has the majority of MA patients, is
referred to as ‘‘LCA severemigraine.’’ Trait-component phenotypes
were recorded directly from the questionnaire data of all patients
fulﬁlling any migraine diagnosis. Table 3 summarizes the propor-
tions of the different phenotypes.
Genotyping
All genotyping was performed in the Finnish Genome Center,
with the same equipment and conditions. The genotyping proce-
dure was conducted with standard methods on the ABI or the
MegaBACE genotyping systems. Genotyping was based on the
LMS-MD10 microsatellite marker set (Applied Biosystems, Foster
City, CA, USA). The marker set uses 387 markers for a 9.5 cM aver-
age intermarker distance and covered all autosomes and the
X chromosome. For the ABI system, genotyping was performed
with the ABI 3730 capillary sequencing instrument, and PCR
products were resolved with the ABI 3730 data collection software
and sized with the Genemapper software package from Applied
Biosystems. For the MegaBACE system, capillary electrophoresis
employed by the MegaBACE 1000 DNA Sequencing System (GE
Healthcare Bio-Sciences, Piscataway, NJ, USA), was used for sepa-
rating DNA fragments. Alleles for this system were called by the
MegaBACE Genetic Proﬁler 1.5 software. In addition, seven more
markers were genotyped at chromosome 10q22-q23, resulting in
a coverage of 2.21 cM average intermarker distance from marker
Table 3. Number of Affecteds, Frequencies of Individual
Trait Components, and the Gender Proportions of Those
Affected for All Traits and Trait Groups within the Study
Samples
Phenotype (n) of Total Finns Australians Males Females
Total subjects (1675) - 61% 39% 39% 61%
MA end diagnosis (621) 37% 41% 31% 21% 49%
Latent class CL23a (790) 47% 48% 45% 29% 60%
Latent class CL3 (599) 36% 36% 36% 15% 49%
Attack length (781) 47% 45% 49% 35% 60%
Unilaterality (727) 43% 48% 36% 30% 52%
Pulsation (778) 46% 49% 42% 35% 54%
Intensity (1033) 62% 67% 53% 46% 71%
Nausea/vomiting (870) 52% 55% 48% 34% 63%
Photophobia (918) 55% 59% 47% 37% 66%
Phonophobia (826) 49% 50% 47% 31% 61%
a Refers to a combination of latent classes CL2 and CL3.erican Journal of Human Genetics 82, 1051–1063, May 2008 1053
D10S218 to D10S2470. The Finnish replication sample was geno-
typed only for these markers. All genotypes were veriﬁed by hu-
man inspection, and the PedCheck1.126 computer program was
used for detecting genotyping errors.
For the follow-up association study, an Illumina Golden Gate
assay (Illumina, San Diego, CA, USA) was used to genotype 1536
single-nucleotide polymorphisms (SNPs) in altogether 564 indi-
viduals across the region deﬁned by the shared haplotype
(chr10, 78.233–88.884 Mb, NCBI build 35) at the Broad Institute.
These 1536 SNPs on chromosome 10 (build 35, 78.23388.884
Mb) were selected as tag-SNPs with Haploview’s Tagger-option
with CEU population in the HapMap SNP set (v21), and we
selected to tag SNPs with minor allele frequency R10% and r2
threshold of R0.8. The selected 1536 tag SNPs tagged 94% of
the 8290 SNPs (MAF R0.10) with r2 R0.8 and 99% of the SNPs
with r2 R0.5. The Illumina BeadStudio software version 3.1.0.0
(Illumina) was used for calling the SNP genotypes, and each SNP
was evaluated for quality of the genotypes. Only samples that
had success rate of R97% and SNPs with 95% were considered
in the statistical analyses of the SNP data, and thus of the 1536
original SNPs, 1323 passed our rigorous quality control. Because
of the difﬁculty involved in genotyping the region around the
known CNV at ~81.3 Mb, there were no successfully genotyped
SNPs between 81,058,202 and 81,674,055 base pairs, resulting in
a 615 kilobase gap in the assay coverage.
Linkage and Association Analysis
For the genome-wide analyses, multipoint nonparametric linkage
analysis was performed with the MERLIN computer program.27
TheMERLINNPLpairs and NPLqtl Z score statistics are implemented
in the general framework of Whittemore and Halpern.28 These Z
scores are used by MERLIN to construct a likelihood ratio test for
linkage and deﬁne a LOD score statistic with the exponential mod-
eling procedure of Kong and Cox.29
For the Finnish families, in line with our previous research,8,11
we employed an affecteds-only strategy (i.e., all individuals not
classiﬁed as affected were considered to have an ‘‘unknown’’ phe-
notype) to allow for reduced penetrance, lack of environmental
exposure, etc. We used the nonparametric MERLIN NPLpairs Z
score statistic30 to test for increased allele sharing among affected
individuals. To avoid biasing our results on possible overrepre-
sented rare variants in a few large families, we also analyzed the
Finnish genome-wide sample as nuclear families. For consistency
with the previous Australian genome-wide linkage scan,8 in order
to use the information from unaffected individuals, we used a
nonparametric quantitative trait linkage (NPLqtl Z-score) statistic
for the analyses of the Australian families in order to obtain addi-
tional linkage information from unaffected individuals. In this
analysis, affected individuals were coded as ‘‘1,’’ unaffected indi-
viduals were coded as ‘‘0,’’ and those with missing phenotypes
were coded as ‘‘x.’’ The validity of this, as well as the original re-
gression Haseman-Elston approach31 for binary traits, has been
proven consistently.32 For the combined genome-wide analysis
of Finnish and Australian pedigrees, we used nuclear families to
avoid biasing the signal because of the larger Finnish families, and
the NPLpairs Z-score statistic was used with the usual ‘‘affection’’
phenotype coding of 0, 1, and 2 to represent unknown/missing,
unaffected, and affected individuals, respectively. In addition,
we performed a sex-speciﬁc analysis by alternatively considering
only the affected females or males as ‘‘true’’ affecteds and treating
the affecteds of the other gender as having an ‘‘unknown’’ pheno-
type. In addition, a haplotype shared-segment analysis was1054 The American Journal of Human Genetics 82, 1051–1063, Maperformed in the Finnish families. The GENEHUNTER software,33
version 2.1_r5beta, was used for construction of pedigrees showing
the paternal andmaternal haplotypes for the additionalmarkers at
this locus for the families showing a family-speciﬁc NPLall score
greater than 1.00 at the location of the highest LOD score.
For the follow-up association study, PLINK software version
1.0034 was used for all analyses. We employed the DFAM analysis
(dfam) to detect association in the combined set of trios and the
case-control subjects. Results were corrected through adaptive
permutation (perm) with PLINK default settings.
Signiﬁcance Limits
To account for all the phenotypes tested, we needed to apply robust
correction formultiple testing. To start, rather than touse the signif-
icance thresholds of Lander-Kruglyak (L-K),35 conservative for mi-
crosatellite-based linkage scans due to the unrealistic assumption
of having complete (100%) inheritance information, we estimated
the signiﬁcance thresholds for affected sibpair analysis of 400
markers by using the formulae presented by Feingold et al.36 The
L-K threshold for signiﬁcant evidence of linkage (p ¼ 0.000022,
corresponding to a standard LOD score of 3.63) is decreased to
p ¼ 0.00009 (corresponding to a LOD score of 3.05). Similarly, the
threshold for suggestive linkage is reduced from p ¼ 0.00074
(LOD score of 2.19) to p ¼ 0.0023 (LOD score of 1.74).37 These
theoretically derived thresholds are consistent with those obtained
via simulation by ourselves8 and others.38–41 To correct for the
multiple phenotypes (including the sex-speciﬁc analyses) used in
this study, we applied the program matSpD (see Web Resources) to
estimate the equivalent total number of independent tests per-
formed (six), resulting in robust Bonferroni-corrected signiﬁcance
thresholds of 6.18 [5.40 þ log10(6)] for highly signiﬁcant evidence
of linkage, 3.83 [3.05þ log10(6)] for signiﬁcant evidence of linkage,
and 2.52 [1.74 þ log10(6)] for suggestive evidence. For the replica-
tion set, we applied the L-K replication threshold of LOD 1.8
(nominal evidence of linkage, p¼ 0.01, for ﬁve independent tests),
equal to ﬁnemapping a 10 cM area.35 For the follow-up association
study, weused the snpSpDprogram (seeWebResources) to estimate
the number of independent SNP tests after accounting for LD
(761.7), resulting in Bonferroni-corrected signiﬁcance threshold
of 6.733 105.
Results
Genome-wide multipoint linkage analysis of 387 microsa-
tellite markers was performed in two independent study
samples; this was followed by an analysis of a locus-speciﬁc
Finnish replication sample. All samples were analyzed
separately as well as jointly. A locus on 10q22-q23 showed
signiﬁcant evidenceof linkage inFinns aswell as in the joint
analysis and suggestive evidence of linkage in the Austra-
lian study. A sex-speciﬁc analysis, considering only females
as affected, improved the linkage signal to the level of
highly signiﬁcant evidenceof linkage.Noother loci showed
linkage in both samples. Population-speciﬁc loci on 2p12,
8q12, and Xp22 showed suggestive evidence of linkage.
Genome-wide Population-Speciﬁc Linkage Analysis
We ﬁrst wanted to identify regions linked to any of the
migraine traits in the individual study populations. Iny 2008
the Finnish study sample, the MERLIN NPLpairs analysis
showed signiﬁcant evidence of linkage to a locus on
10q22-q23. The highest LOD score (5.50) was observed at
103 cM with the TCA unilaterality phenotype, with the
95% CI placing the locus between 99 cM and 114 cM. Sig-
niﬁcant evidence of linkage at this locus was also shown by
the MA end diagnosis, LCA migrainous headache, and ﬁve
additional TCA phenotypes (see Table 4). In the Finnish
study sample, no other chromosomal region showed
signiﬁcant evidence of linkage, and only two regions
showed suggestive evidence of linkage (on 2p12, NPLpairs
Table 4. Phenotypes Showing Genome-wide Significant LOD













TCA unilaterality 5.18 0.00 0.62
TCA pulsation 4.24 3.50 4.62
TCA pain intensity 5.03 1.32 3.75
TCA nausea/vomiting 3.90 0.25 2.88
TCA photophobia 4.22 0.11 2.40
TCA phonophobia 5.03 0.00 1.63
Note that numbers in italics represent genome-wide significant evidence of
linkage (LOD > 3.83).The AmLOD score 2.60 at 100 cM with TCA pulsation phenotype;
1.93 for MA end diagnosis, and 1.74 for LCA migraine and
on Xp22, NPLpairs LOD score 2.96 at 39 cM with TCA
pulsation phenotype, 1.19 for MA end diagnosis, and 1.72
for LCA severe migraine), although a previously detected
locus on 18q129–12 showed sufﬁcient evidence for replica-
tion (NPLpairs LOD 2.46 at 86 cM with TCA attack-length
phenotype, 0.21 for MA end diagnosis, and 0.41 for LCA
migrainousheadache). Encouragingly, the10q22-q23 locus
is robustly replicated in the Australian study sample with
a highly suggestive NPLqtl score of 3.50 at 100 cM with
the TCA pulsation trait, with the 95% CI located between
94 cM and 115 cM. Other phenotyping methods provided
modest signals in the Australian study sample at the
10q22-q23 locus. In the Australian sample, suggestive evi-
dence of linkage was found to a region on 8q12 (NPLqtl
LOD of 2.63 at 86 cM with the TCA pain intensity pheno-
type, 0.29 for MA end diagnosis, and 1.27 for LCAmigrain-
ous headache), and a previously detected locus on 14q21
was replicated (NPLqtl LOD 2.23 at 26 cM with TCA pain
intensity phenotype, 0.24 for MA end diagnosis, and 1.68
for LCA migrainous headache). The genome-wide results
for all traits are shown in Figure 1.
Genome-wide Joint Analysis of Australian
and Finnish Study Samples
Results of a joint MERLIN NPLpairs analysis yielded signiﬁ-
cant evidence of linkage to the same region as in theFigure 1. Maximum LOD Scores in the Genome-wide Screen
The graphs show values across all phenotypes and phenotyping methods for the Finnish study sample in the NPLpairs analysis, the Aus-
tralian study sample in the NPLqtl analysis, and the NPLpairs analysis performed on both study samples together. The dotted line denotes
the level of significant evidence of linkage (LOD > 3.83).erican Journal of Human Genetics 82, 1051–1063, May 2008 1055
Figure 2. Genome-wide Comparison of the Three Genotyping Methods in the Combined Study Sample
The graphs show the highest LOD score detected with each phenotyping method in the joint analysis of the two genome-wide screens in
the NPLpairs analysis performed with both study samples together. The horizontal lines and boxes indicate the maximum LOD scores at
10q22-q23 for each method. The dotted line denotes the level of significant evidence of linkage (LOD > 3.83).individual analysis, between 98 cM and 117 cM at 10q22-
q23. The highest LOD score (4.62) was found at 102 cM
with the TCA pulsation phenotype, and signiﬁcant evi-
dence of linkage was also detected with TCA pain-intensity
phenotypes (see Table 4). Neither of the regions showing
suggestive linkage in only one sample showed evidence of
linkage above nominal level (2p12 highest NPLpairs LOD
score 0.57, for 8q12, 1.01; and for Xp22, 1.36) in the joint
analysis. Comparison of results from each of the three
phenotyping methods in the joint analysis is presented in
Figure 2.
Fine Mapping the Locus on 10q22-q23
Seven additional markers were genotyped in both initial
study samples to increase the available linkage informa-
tion across the implicated 10q22-q23 region. When in-
cluding those markers in the joint-linkage analysis, the
highest peak was found at 106 cM (NPLpairs LOD score of
4.11 with the TCA pulsation phenotype, 1.28 for MA end
diagnosis, and 2.16 for LCA migrainous headache). These
results are detailed in Figure 3.
Finnish Replication Study
We genotyped an independent Finnish replication
sample of 27 families for the seven additional microsatel-
lite markers at the 10q22-q23 locus to further strengthen
the evidence of linkage. Because the families providing
most of the linkage signals to the 10q22-q23 locus in the1056 The American Journal of Human Genetics 82, 1051–1063, Maygenome-wide study were found to suffer from a severe
form of migraine that included some hemiparesis symp-
toms (although not severe enough to qualify as familial
or sporadic hemiplegic migraine), this clinical phenotype
was used as the basis of selecting the families for the repli-
cation study (see Table 5). In the linkage analysis, the high-
est peak was found at 102 cM with the TCA pulsation
Figure 3. Positioning the Linkage Peaks on Chromosome 10
The graphs show maximum attained LOD scores in each study sam-
ple in the Merlin multipoint analyses, including the seven addi-
tional microsatellite markers. The bracket denotes the area covered
by the family-specific haplotype segregating with the affection
status.2008
phenotype (NPLpairs LOD score of 2.41), sufﬁcient for rep-
lication (LOD > 1.8).
Sex-Speciﬁc Findings
In line with previous studies11,12 that have suggested
sex-speciﬁc effects at linked loci, we performed a sex-spe-
ciﬁc analysis for chromosome 10. In the Australian study,
sex-speciﬁc analyses yielded no improvement in the link-
age signal. However, in the Finnish study sample, consider-
ing only affected females yielded a considerable increase in
the LOD score, resulting in highly signiﬁcant evidence of
linkage with a number of phenotypes, including the MA
end diagnosis. The highest NPLpairs LOD score was 7.68
(at 103 cM, TCA phonophobia phenotype, 4.37 for MA
end diagnosis, and 5.33 for LCA migrainous headache).
In contrast, considering only affected males, the linkage
signal was below the level of nominal evidence of linkage
(highest NPLpairs LOD score 0.20 at the same location).
For the Finnish females, all of the studied phenotypes
except LCA severe migraine showed signiﬁcant evidence
of linkage. For the joint analysis, considering only females
and nuclear families produced a signiﬁcant LOD score of
4.11 (at 106 cM with the TCA photophobia phenotype,
2.52 for MA end diagnosis, and 3.19 for LCA migrainous
headache). Female-speciﬁc results are detailed in Figure 4.
Table 5. The Number and Proportion of Migraineurs










n in total sample 441 (-) 690 (-) 324 (-)
with hemiparesis
symptoms
42 (9.5%) 67 (9.7%) 51 (15.7%)
with hemisensory
symptoms
87 (19.7%) 117 (17.0%) 70 (21.6%)
Figure 4. Female-Specific Multipoint Linkage Results on
Chromosome 10
The graphs show the results obtained with the TCA pulsation pheno-
type, which gives the highest evidence of linkage in each sample.The AmHaplotype Analysis at 10q22-q23
Because the Finnish study sample is from a population
with a limited number of founders and multiple bottle-
necks in the population history, we performed a haplotype
shared-segment analysis to further restrict the linked re-
gion and identify the most probable location of the disease
predisposing variants. The analysis was conducted in those
21 Finnish families that had a family-speciﬁc nonparamet-
ric linkage (NPL) score greater than 1.00 (as measured by
GENEHUNTER) at the location of the highest linkage sig-
nal (97.5 cM), both from the genome-wide sample and
the replication sample. These families contain 178 individ-
uals, of which 99 (or 56%) are considered affected accord-
ing to our clinical MA end diagnosis. Ninety-ﬁve percent
(94 out of 99 subjects) shared the family-speciﬁc haplotype
between markers D10S1786 (103.3 cM) and D10S1686
(104.9 cM). Considering the locations of the ﬂanking
markers (D10S569 at 97.5 cM and D10S1687 at 107.3
cM), the detected haplotype is between 1.6 and 9.8 cM
wide (1.6 – 9.6 Mb). Restricting the area to this region
Figure 5. Haplotype Distribution among the Finnish Families
with Family-Specific LOD Scores over 1.00 at the Location of
the Highest Linkage Signal in Finns, 103 cM
This figure shows the family-specific haplotype segregatingwith the
affection status on chromosome 10q22-q23, for the roughly 30 Mb
area spanning the markers D10S1652 and D10S185 around the
linkage peak. The lightly shaded area represents the haplotype block
shared by affected members of the family, and the darker shading
indicates the region shared by all affected family members across
families. ‘‘N/a’’ denotes an unavailable genotype, and ‘‘n’’ denotes
multiple different alleles in affected family members. The bottom
of the figure shows the largest transcribed genes in the region, in
scale relative to the distances between the microsatellites.erican Journal of Human Genetics 82, 1051–1063, May 2008 1057
Figure 6. Results of the Follow-Up
Association Study that Used 39 Trios,
256 Unrelated Cases, and 230 Controls
in the DFAM Association Analysis
The dotted line at the top of the figure de-
notes the minimum known length of the
family-specific segregating microsatellite
haplotype (see Figure 6), and the solid
line denotes its maximum possible length.
The bottom of the figure shows the largest
transcribed genes in the region, in scale
according to the isoform with the largest
genomic size, as well as the area of the
known CNV.was accomplished on the basis of three and four informa-
tive recombinations, respectively. Results of this analysis
are detailed in Figure 5.
Follow-up Association Study
The trio and case-control samples were analyzed with
the DFAM analysis option of PLINK,34 which allows for
the combination of trio and case-control data. None of the
SNPs showed association exceeding the signiﬁcance
threshold of 6.73 3 105. The highest association was de-
tected with SNP rs1873695 (p value 9.22 3 104; KCNMA1
intronic), with several adjacent SNPs showing a similar
level of association (rs2131218: 0.0035, rs16934025:
0.0019). Three other regions show association scores under
the 0.005 level with several adjacent markers: rs10458664
(0.0035, outside any known gene), rs7906586 (p ¼ value
0.0025, outside any known gene), and rs2691052 (0.002,
outside any known gene) (see Figure 6 for results).
Discussion
In the present study, we detected highly signiﬁcant evi-
dence of linkage to 10q22-q23 and replicated the ﬁnding
in two diverse populations. The locus was detected with
all three phenotyping methods used, which alternatively
concentrate on the presence of aura, IHS symptom cluster-
ing, or the individualmigraine symptoms. The consistency
of linkage ﬁndings across studies with different ascertain-
ment schemes and phenotyping methods provides com-
pelling evidence for the strength of this ﬁnding.
As is often the case in complex traits, the linkagepeaks de-
ﬁning the detected 10q22-q23 region are relatively broad
(between 8 cM and 21 cM wide, depending on the method
of analysis), and the number of susceptibility loci within
this region cannot be predicted. However, given that the
analysis peaks all converge on a narrow (under 5 cM) area,
which contains the area deﬁned by the shared-segment
analysis, there is therefore strong evidence for constraining
the peak between 97.5 cM and 104.9 cM (see Figure 3). This
interval contains two obvious functional candidate genes.
KCNMA1 is a Maxi-K, calcium-level detecting potassium1058 The American Journal of Human Genetics 82, 1051–1063, Maychannel, which is involved in ion transport in a similar
manner to the three known genes involved in the molecu-
lar pathology of familial hemiplegic migraine (see Table
S1A), a related Mendelian disorder (CACNA1A, ATP1A2,
and SCN1A, MIM 141500, MIM 602481, and MIM
609634, respectively).NRG3, located directly in themiddle
of the narrowest peak, is a gene belonging to the neuregulin
family of growth and differentiation factors that are related
to epidermal growth factor, which plays a role in
oligodendrocyte survival.
Overall, there is an encouraging consistency between
the results of this study and the previous Finnish11 and
Australian8 studies. An overview of current and previous
results at 10q22-q23 can be seen in Figure 7. The three
other chromosomal areas showing evidence of signiﬁcant
or suggestive linkage to migraine in more than one report
and in more than one population prior to this study are
on chromosomes 4q21-q31, 15q11-q13, and 18q12. The
previously reported chromosome 4q locus seems to be ex-
ceptionally broad; whereas the linkage in the Icelandic
population is reported at 4q21,12 previous Finnish studies
identiﬁed two peaks at 4q249 and at 4q28-q31,11 making
the total linked region up 50 cM wide. In this study, we
Figure 7. Previously Reported Migraine Linkage Results at the
10q22-q23 Locus Plotted Together with Results of This Study2008
were unable to replicate this locus, although closer exami-
nation of the family-speciﬁc results reveals the existence of
a subset of families (approximately one-fourth of the total
sample in both Australians and Finns) with family-speciﬁc
Z scores up to 2.4, even though the overall evidence of
linkage was nominal. This was also the case with the previ-
ously reported 17p13 locus.11 Similarly, the previously
reported 15q11-q13 locus was undetectable in our study.
The chromosome 18q12 locus has been detected in both
the Icelandic12 and Finnish samples9,11 (although the Ice-
landic linkage was observed after a broader deﬁnition of
migraine was applied and only females considered as
affecteds), as well as in the previous Australian study.10
This locus is also replicated here, with the same TCA at-
tack-length phenotype as in the previous Finnish study,
bringing the total number of study samples showing link-
age to this locus to four. Finally, three loci previously linked
to migraine in only one study sample are also replicated,
two in their respective populations: the locus on 8q21 de-
tected in Australians (NPLqtl LOD score of 2.63) is within
10 cM from a previously detected Australian locus,8 a previ-
ously reported locus on 14q21 detected in a large Italian
family14 is replicated in the Australian sample (NPLqtl LOD
score of 2.21 at 26 cM), and the peak on Xp22 (NPLpairs
LOD score of 3.05 in Finns) is only 7 cM from a locus on
Xp21, detected in the previous Finnish study.9,11 In total,
of the seven loci reported in Finns so far (4q, 10q*, 12q,
15q, 17p, 18q*, and Xp*), this study replicates three (de-
noted by asterisks), as well as three of the ﬁve reported in
Australians (5q, 8q*, 10q*, 13q, and 18p-18q*). Finally,
given that only one (2p12) of the four loci with suggestive
or higher evidence of linkage in this study (2p, 8q, 10q,
and Xp) has not been reported previously, overall the
extended phenotyping methods seem to facilitate replica-
tion, especially considering that only one locus (4q21-q24)
has been replicated with end-diagnosis-based approaches.
An overview of results at each OMIM-listed migraine loci
can be seen in Table S1B.
A closer look into previous migraine scans showed that
the 10q22-q23 locus had been implicated in our two
scans8,11 with suggestive evidence of linkage. The present
and the two previous studies suggest that complementing
the classical clinical migraine diagnosis with alternative
phenotyping strategies can facilitate the identiﬁcation of
susceptibility-locus identiﬁcation. Both the trait-compo-
nent analysis and the latent-class analysis approaches
have proven useful in this respect, although they have dif-
ferent premises and represent conceptual approaches. It is
of interest to note that if only the MA end diagnosis had
been used as the study phenotype, the 10q22-q23 locus
would have been detected with suggestive or signiﬁcant
evidence of linkage in only one of the ﬁve recent migraine
study samples in the Australian and Finnish populations
(including the three reported here; corresponding success
rates 2/5 for LCA, and 5/5 for TCA).8,11 There are two
likely explanations for the greater sensitivity of TCA and
LCA over the clinical diagnosis: (1) LCA and especiallyThe AmTCA may better reﬂect underlying processes in migraine
pathophysiology, and/or (2) these two methods can utilize
the questionnaire-based information in a more optimal
way to ﬁnd informative individuals within the MA and
MO patient pools, thus including more cases and informa-
tive meioses for the linkage analysis. Although advantages
and disadvantages exist for any analytical approach, these
and previous results suggest that the trait-component
analysis may offer substantial gains over analysis of clini-
cal (migraine with aura) or empirical (e.g., LCA) end diag-
noses especially when the diagnostic information is in-
complete. Given that both the end diagnosis and the
latent classes are based on combining information from
phenotype proﬁles, it is perhaps not surprising that they
both lose more power compared to TCAwhen the amount
of available information is less than complete. This could
explain the differences in results between the phenotyping
methods in the current Australian study sample. Further-
more, using individual trait components directly allows ad-
ditional efforts to be concentrated on increasing the size of
the study samples,without theneed to collect progressively
more and more detailed clinical diagnostic information to
optimize the formulationof the enddiagnosis.On theother
hand, it is possible that theTCAﬁndings are the result of de-
tecting genes involved in the symptom-speciﬁc processes
and not involved in the primary pathophysiology of
migraine.
The role of pulsating pain trait is of particular interest.
Repeatedly, pulsation seems to be the most sensitive indi-
vidual trait for linkage-based locus identiﬁcation, provid-
ing all of the highest results in the Australian sample and
many of those in the Finnish sample. This is evident in
the previous two other genome-wide scans as well; the
best signal in the previous Australian study (5q21)8 is pre-
dominantly driven by pulsation, as is the best locus in the
previous Finnish study (17p13),11 which showed signiﬁ-
cant evidence of linkage only with pulsation. In addition,
it plays a major role in the 10q22-q23 results in this study.
The reason for this remains speculative. One possible ex-
planation is that pulsating pain is a symptom that is
more easily recognized by patients and thus is more consis-
tently recorded in interviews and questionnaires. This does
not, however, exclude the possibility that pulsation is in-
deed the most characteristic symptom of a particular type
of migraine and reﬂects some yet-unknown neurovascular
mechanism and is thus associated with speciﬁc pathophys-
iological pathways. It should also be noted that pulsation
or any other TCA trait was not used in the sample ascer-
tainment; that is, the sample selection process is naive
with respect to the traits. Another interesting ﬁnding is
the role of hemiparesis symptoms; because the families
contributing most to the 10q22-q23 locus suffered from
amore severe form of migraine, they have a higher propor-
tion of hemiplegic symptoms. After the families for the
replication study were selected for a higher prevalence of
this severe form, a similar effect was observed in the repli-
cation study, further underlining the contribution of thiserican Journal of Human Genetics 82, 1051–1063, May 2008 1059
clinical phenotype to the 10q22-q23 locus. Thus, we were
able to extract a part of the clinical spectrum of migraine,
concentrate on it in case selection, and predict and subse-
quently demonstrate linkage to a particular genetic locus
with a small number of patients targeted for that particular
aspect, which is both a novel and an encouraging ﬁnding.
In addition, on the basis of the known ion-channel-
centered molecular pathology of familial hemiplegic
migraine,42–44 this supports KCNMA1 as a compelling can-
didate gene. Lastly, the difference between overall and
sex-speciﬁc linkage results at 10q22-q23 seem to reﬂect a
predominantly female-dominated inheritance pattern in
the Finnish families linked to this locus; such a ﬁnding is
somewhat to be expected because of the higher prevalence
of migraine in women. However, this is not enough to ex-
plain the considerable increase in linkage signal when con-
sidering only females as affected. The same effect, though
to a smaller degree, can also be seen in the Australian study
sample, as well as in a previous Finnish11 and an Icelandic
study.12 These results suggest that using gender as a covari-
ate in future migraine studies might provide increase in
power for the detection of new variants. Sex might also
be an indicator for male-speciﬁc environmental or behav-
ioral characteristics that hide the signal in men, perhaps
related to the better ability of women to detect and elabo-
rate on symptoms and signs in headache and migraine;
whether this is related also to higher prevalence of mi-
graine in women also needs to be examined.
Although no SNPs showed signiﬁcant association in the
follow-up study, four potentially interesting regions sup-
port additional studies. The highest association, although
not high enough to be considered signiﬁcant, was ob-
served with one obvious candidate gene, KCNMA1. The
three SNPs with the next highest scores were located out-
side known coding genes. However, given the high linkage
signal in the region and the variance among the family-
speciﬁc affected haplotypes, it is possible that this locus
contains multiple susceptibility variants affecting mi-
graine but that the sample used is too small to sufﬁciently
discern between them. Thus, larger studies are warranted
to see whether these ﬁndings can be replicated. The poten-
tial, suggestive association to KCNMA1 is intriguing be-
cause the established FHM mutations are all located in
proteins involved in ion transport.
A timely question is how linkage signals, as the chromo-
some 10q22-q23 locus reported here, correspond to associ-
ation signals in WGA studies. Recent studies provide an
opportunity to compare loci identiﬁed with these two dif-
ferent strategies that are based on different hypothesis. Al-
though linkage studies are best suited to position relatively
penetrant and possibly rare variants, WGA studies are de-
signed to test the ‘‘common-diseases-common-variant’’
hypothesis. Although the number of WGA studies is still
limited, some trends can be observed; there are examples
of identiﬁcation of both previously unidentiﬁed loci and
conﬁrmation of loci identiﬁed in linkage studies. Impor-
tantly, the WGA studies have identiﬁed new robustly rep-1060 The American Journal of Human Genetics 82, 1051–1063, Maylicated loci in regions not previously linked or associated
to disease traits.45–49 However, in cases such as prostate
cancer (8q24)50–52 Crohn’s disease (16q12, NOD2),53,54
type II diabetes (10q23-q26),55–57 and MS (5p13),58,59
some of the strongest associations are observed in regions
where linkage has previously been detected and replicated
in several studies. Thus, it is relevant to hypothesize that
the linkage to chromosome 10q22-q23 region detected
consistently in several migraine study samples could repre-
sent a region where a relatively highly penetrant and per-
haps common variant(s) is/are associated to migraine. An-
other possibility is that a strong linkage observed in several
study samples indicates that there are several susceptibility
variants or even genes within the linked locus.
Regardless of the various constraints involved, we de-
tected strong linkage at the 10q22-q23 locus in all three
samples assessed in this study. The detection of linkage
to the 10q22-q23 locus with different phenotyping
methods and different ascertainment protocols provides
strong support for the presence of a gene(s) in this region
inﬂuencing migraine susceptibility. In addition, our study
demonstrates the advantages of using of IHS clinical traits
directly in migraine genetics and allowed the conﬁrmation
of a number of previously reported genomic regions being
coinherited with migraine.
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Acknowledgments
This study was supported by the Sigrid Juselius Foundation, the
Academy of Finland (200923 to A.P.; 00213 to M.W.), the Helsinki
UniversityCentralHospital, FinnishAcademyCenter of Excellence
for Complex Disease Genetics, the EuroHead project (LSHM-CT-
2004-504837), the GenomEUtwin project (QLG2-CT-2002-
01254), the Oxnard Foundation, the Helsinki Biomedical Graduate
School, the Finnish Cultural Foundation (to V.A.), the Finnish
Neurology Foundation, and National Institutes of Health (RO1
NS37675 toA.P.), National Institute onAlcohol Abuse andAlcohol-
ism (United States) grants AA007535, AA013320, AA013326,
AA014041,AA07728,AA10249, andAA11998,andNationalHealth
andMedical Research Council (NHMRC, Australia) grants 941177,
951023, and 241916. D.R.N. and G.W.M were supported by
NHMRC R.D. Wright and Senior Research Fellowships. The Broad
Institute Center for Genotyping and Analysis is supported by grant
U54 RR020278 from the National Center for Research Resources.
For the Australian study, we thank Dixie Statham, Clare Redfern,
Anjali Henders, Megan Campbell, David Smyth, Scott Gordon; we
also thank the twins, for their generous participation. For the Finn-
ish study,we thankRaija-LeenaHalme,Heikki Tarkkila and the staff
of Finnish Genome Center for their contribution and the Finnish
migraine patients yet again for their invaluable participation.
Received: November 28, 2007
Revised: February 4, 2008
Accepted: March 3, 2008
Published online: April 17, 20082008
Web Resources
The URLs for data presented herein are as follows:
matSpD, http://genepi.qimr.edu.au/general/daleN/matSpD/
Migraine Questionnaire used in the SSAGA-1 ‘‘Older Cohort,’’
http://genepi.qimr.edu.au/general/daleN/Migraine/
SSAGA1MigraineQuestionnaire.pdf
Migraine Questionnaire used in the Twin89 ‘‘Younger Cohort,’’
http://genepi.qimr.edu.au/general/daleN/Migraine/
Twin89MigraineQuestionnaire.pdf





1. Stovner, L.J., Zwart, J.A., Hagen, K., Terwindt, G.M., and Pasc-
ual, J. (2006). Epidemiology of headache in Europe. Eur. J.
Neurol. 13, 333–345.
2. Launer, L.J., Terwindt, G.M., and Ferrari, M.D. (1999). The
prevalence and characteristics of migraine in a population-
based cohort: The GEM study. Neurology 53, 537–542.
3. Mulder, E.J., Van Baal, C., Gaist, D., Kallela, M., Kaprio, J.,
Svensson, D.A., Nyholt, D.R., Martin, N.G., MacGregor, A.J.,
Cherkas, L.F., et al. (2003). Genetic and environmental inﬂu-
ences on migraine: a twin study across six countries. Twin
Res. 6, 422–431.
4. Russell, M.B., and Olesen, J. (1995). Increased familial risk and
evidence of genetic factor in migraine. BMJ 311, 541–544.
5. Andlin-Sobocki, P., Jonsson, B., Wittchen, H.U., and Olesen, J.
(2005). Cost of disorders of the brain in Europe. Eur. J. Neurol.
12 (Suppl 1), 1–27.
6. Honkasalo, M.L., Kaprio, J., Winter, T., Heikkila, K., Sillanpaa,
M., and Koskenvuo, M. (1995). Migraine and concomitant
symptoms among 8167 adult twin pairs. Headache 35, 70–78.
7. Larsson, B., Bille, B., and Pederson, N.L. (1995). Genetic in-
ﬂuence in headaches: A Swedish twin study. Headache 35,
513–519.
8. Nyholt, D.R., Morley, K.I., Ferreira, M.A., Medland, S.E.,
Boomsma, D.I., Heath, A.C., Merikangas, K.R., Montgomery,
G.W., and Martin, N.G. (2005). Genomewide signiﬁcant link-
age to migrainous headache on chromosome 5q21. Am. J.
Hum. Genet. 77, 500–512.
9. Wessman, M., Kallela, M., Kaunisto, M.A., Marttila, P., Sobel,
E., Hartiala, J., Oswell, G., Leal, S.M., Papp, J.C., Hamalainen,
E., et al. (2002). A susceptibility locus for migraine with aura,
on chromosome 4q24. Am. J. Hum. Genet. 70, 652–662.
10. Lea, R.A., Nyholt, D.R., Curtain, R.P., Ovcaric, M., Sciascia, R.,
Bellis, C., Macmillan, J., Quinlan, S., Gibson, R.A., McCarthy,
L.C., et al. (2005). A genome-wide scan provides evidence for
loci inﬂuencing a severe heritable form of common migraine.
Neurogenetics 6, 67–72.
11. Anttila, V., Kallela, M., Oswell, G., Kaunisto, M.A., Nyholt,
D.R., Hamalainen, E., Havanka, H., Ilmavirta, M., Terwilliger,
J., Sobel, E., et al. (2006). Trait components provide tools to
dissect the genetic susceptibility of migraine. Am. J. Hum.
Genet. 79, 85–99.
12. Bjo¨rnsson, A., Gudmundsson, G., Gudﬁnnsson, E., Hrafnsdot-
tir, M., Benedikz, J., Skuladottir, S., Kristjansson, K., Frigge,
M.L., Kong, A., Stefansson, K., and Gulcher, J.R. (2003). Local-The Amization of a gene for migraine without aura to chromosome
4q21. Am. J. Hum. Genet. 73, 986–993.
13. Cader, Z.M., Noble-Topham, S., Dyment, D.A., Cherny, S.S.,
Brown, J.D., Rice, G.P., and Ebers, G.C. (2003). Signiﬁcant
linkage to migraine with aura on chromosome 11q24. Hum.
Mol. Genet. 12, 2511–2517.
14. Soragna, D., Vettori, A., Carraro, G., Marchioni, E., Vazza, G.,
Bellini, S., Tupler, R., Savoldi, F., and Mostacciuolo, M.L.
(2003). A locus for migraine without aura maps on chromo-
some 14q21.2-q22.3. Am. J. Hum. Genet. 72, 161–167.
15. Carlsson, A., Forsgren, L., Nylander, P.O., Hellman, U., Fors-
man-Semb, K., Holmgren, G., Holmberg, D., and Holmberg,
M. (2002). Identiﬁcation of a susceptibility locus for migraine
with and without aura on 6p12.2-p21.1. Neurology 59, 1804–
1807.
16. International Headache Society (1988). Classiﬁcation and
diagnostic criteria for headache disorders, cranial neuralgias
and facial pain. Headache Classiﬁcation Committee of the
International Headache Society. Cephalalgia 8, 1–96.
17. International Headache Society (2004). The International
classiﬁcation of headache disorders: 2nd edition. Cephalalgia
24 (Suppl 1), 9–160.
18. Nyholt, D.R., Gillespie, N.G., Heath, A.C., Merikangas, K.R.,
Duffy, D.L., and Martin, N.G. (2004). Latent class and genetic
analysis does not support migraine with aura and migraine
without aura as separate entities. Genet. Epidemiol. 26,
231–244.
19. Blau, J.N. (1995). Migraine with aura and migraine without
aura are not different entities. Cephalalgia 15, 186–190.
20. Ligthart, L., Boomsma, D.I., Martin, N.G., Stubbe, J.H., and
Nyholt, D.R. (2006). Migraine with aura andmigraine without
aura are not distinct entities: Further evidence from a large
Dutch population study. Twin Res. Hum. Genet. 9, 54–63.
21. Kallela, M., Wessman, M., and Fa¨rkkila¨, M. (2001). Validation
of a migraine speciﬁc questionnaire for use in family studies.
Eur. J. Neurol. 8, 61–66.
22. Heath, A.C., Bucholz, K.K., Madden, P.A., Dinwiddie, S.H.,
Slutske, W.S., Bierut, L.J., Statham, D.J., Dunne, M.P., Whit-
ﬁeld, J.B., and Martin, N.G. (1997). Genetic and environmen-
tal contributions to alcohol dependence risk in a national
twin sample: Consistency of ﬁndings in women andmen. Psy-
chol. Med. 27, 1381–1396.
23. Heath, A.C., Howells, W., Kirk, K.M., Madden, P.A., Bucholz,
K.K., Nelson, E.C., Slutske, W.S., Statham, D.J., and Martin,
N.G. (2001). Predictors of non-response to a questionnaire
survey of a volunteer twin panel: Findings from the Australian
1989 twin cohort. Twin Res. 4, 73–80.
24. Merikangas, K.R., Dartigues, J.F., Whitaker, A., and Angst, J.
(1994). Diagnostic criteria for migraine. A validity study. Neu-
rology 44, S11–S16.
25. Stewart, W.F., Staffa, J., Lipton, R.B., and Ottman, R. (1997).
Familial risk of migraine: A population-based study. Ann. Neu-
rol. 41, 166–172.
26. O’Connell, J.R., andWeeks, D.E. (1998). PedCheck: A program
for identiﬁcation of genotype incompatibilities in linkage
analysis. Am. J. Hum. Genet. 63, 259–266.
27. Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R.
(2002). Merlin–rapid analysis of dense genetic maps using
sparse gene ﬂow trees. Nat. Genet. 30, 97–101.
28. Whittemore, A.S., and Halpern, J. (1994). A class of tests for
linkage using affected pedigree members. Biometrics 50,
118–127.erican Journal of Human Genetics 82, 1051–1063, May 2008 1061
29. Kong, A., and Cox, N.J. (1997). Allele-sharing models: LOD
scores and accurate linkage tests. Am. J. Hum. Genet. 61,
1179–1188.
30. Weeks, D.E., and Lange, K. (1988). The affected-pedigree-
member method of linkage analysis. Am. J. Hum. Genet. 42,
315–326.
31. Haseman, J.K., and Elston, R.C. (1972). The investigation of
linkage between a quantitative trait and amarker locus. Behav.
Genet. 2, 3–19.
32. Elston, R.C., Song, D., and Iyengar, S.K. (2005). Mathematical
assumptions versus biological reality: Myths in affected sib
pair linkage analysis. Am. J. Hum. Genet. 76, 152–156.
33. Kruglyak, L., Daly, M.J., Reeve-Daly, M.P., and Lander, E.S.
(1996). Parametric and nonparametric linkage analysis: A uni-
ﬁed multipoint approach. Am. J. Hum. Genet. 58, 1347–1363.
34. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: A tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
35. Lander, E., and Kruglyak, L. (1995). Genetic dissection of com-
plex traits: Guidelines for interpreting and reporting linkage
results. Nat. Genet. 11, 241–247.
36. Feingold, E., Brown, P.O., and Siegmund, D. (1993). Gaussian
models for genetic linkage analysis using complete high-reso-
lution maps of identity by descent. Am. J. Hum. Genet. 53,
234–251.
37. Rao, D.C., and Province, M.A. (2000). The future of path anal-
ysis, segregation analysis, and combined models for genetic
dissection of complex traits. Hum. Hered. 50, 34–42.
38. Abecasis, G.R., Yashar, B.M., Zhao, Y., Ghiasvand, N.M., Zare-
parsi, S., Branham, K.E., Reddick, A.C., Trager, E.H., Yoshida,
S., Bahling, J., et al. (2004). Age-related macular degeneration:
A high-resolution genome scan for susceptibility loci in a pop-
ulation enriched for late-stage disease. Am. J. Hum. Genet. 74,
482–494.
39. Abecasis, G.R., Burt, R.A., Hall, D., Bochum, S., Doheny, K.F.,
Lundy, S.L., Torrington, M., Roos, J.L., Gogos, J.A., and Kar-
ayiorgou, M. (2004). Genomewide scan in families with
schizophrenia from the founder population of Afrikaners re-
veals evidence for linkage and uniparental disomy on chro-
mosome 1. Am. J. Hum. Genet. 74, 403–417.
40. Suarez, B.K., Duan, J., Sanders, A.R., Hinrichs, A.L., Jin, C.H.,
Hou, C., Buccola, N.G., Hale, N., Weilbaecher, A.N., Nertney,
D.A., et al. (2006). Genomewide linkage scan of 409 Euro-
pean-ancestry and African American families with schizophre-
nia: Suggestive evidence of linkage at 8p23.3-p21.2 and
11p13.1-q14.1 in the combined sample. Am. J. Hum. Genet.
78, 315–333.
41. Wiltshire, S., Cardon, L.R., and McCarthy, M.I. (2002). Evalu-
ating the results of genomewide linkage scans of complex
traits by locus counting. Am. J. Hum. Genet. 71, 1175–1182.
42. Ophoff, R.A., Terwindt, G.M., Vergouwe, M.N., van Eijk, R.,
Oefner, P.J., Hoffman, S.M., Lamerdin, J.E., Mohrenweiser,
H.W., Bulman, D.E., Ferrari, M., et al. (1996). Familial hemi-
plegic migraine and episodic ataxia type-2 are caused by
mutations in the Ca2þ channel gene CACNL1A4. Cell 87,
543–552.
43. De Fusco, M., Marconi, R., Silvestri, L., Atorino, L., Rampoldi,
L., Morgante, L., Ballabio, A., Aridon, P., and Casari, G. (2003).
Haploinsufﬁciency of ATP1A2 encoding the Naþ/Kþ pump1062 The American Journal of Human Genetics 82, 1051–1063, Mayalpha2 subunit associated with familial hemiplegic migraine
type 2. Nat. Genet. 33, 192–196.
44. Dichgans, M., Freilinger, T., Eckstein, G., Babini, E., Lorenz-
Depiereux, B., Biskup, S., Ferrari, M.D., Herzog, J., van den
Maagdenberg, A.M., Pusch, M., and Strom, T.M. (2005). Muta-
tion in the neuronal voltage-gated sodium channel SCN1A in
familial hemiplegic migraine. Lancet 366, 371–377.
45. Scott, L.J., Mohlke, K.L., Bonnycastle, L.L., Willer, C.J., Li, Y.,
Duren, W.L., Erdos, M.R., Stringham, H.M., Chines, P.S., Jack-
son, A.U., et al. (2007). A genome-wide association study of
type 2 diabetes in Finns detects multiple susceptibility vari-
ants. Science 316, 1341–1345.
46. Maller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D.,
Daly, M.J., and Seddon, J.M. (2006). Common variation in
three genes, including a noncoding variant in CFH, strongly
inﬂuences risk of age-related macular degeneration. Nat.
Genet. 38, 1055–1059.
47. Gudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthors-
son, J.T., Thorleifsson, G., Manolescu, A., Rafnar, T., Gudb-
jartsson, D., Agnarsson, B.A., Baker, A., et al. (2007). Two var-
iants on chromosome 17 confer prostate cancer risk, and the
one in TCF2 protects against type 2 diabetes. Nat. Genet. 39,
977–983.
48. Todd, J.A., Walker, N.M., Cooper, J.D., Smyth, D.J., Downes,
K., Plagnol, V., Bailey, R., Nejentsev, S., Field, S.F., Payne, F.,
et al. (2007). Robust associations of four new chromosome re-
gions from genome-wide analyses of type 1 diabetes. Nat.
Genet. 39, 857–864.
49. Saxena, R., Voight, B.F., Lyssenko, V., Burtt, N.P., de Bakker,
P.I., Chen, H., Roix, J.J., Kathiresan, S., Hirschhorn, J.N.,
et al. (2007). Diabetes Genetics Initiative of Broad Institute
of Harvard and MIT, Lund University, and Novartis Institutes
of BioMedical Research. Genome-wide association analysis
identiﬁes loci for type 2 diabetes and triglyceride levels.
Science 316, 1331–1336.
50. Amundadottir, L.T., Sulem, P., Gudmundsson, J., Helgason, A.,
Baker, A., Agnarsson, B.A., Sigurdsson, A., Benediktsdottir,
K.R., Cazier, J.B., Sainz, J., et al. (2006). A common variant as-
sociated with prostate cancer in European and African popula-
tions. Nat. Genet. 38, 652–658.
51. Haiman, C.A., Patterson, N., Freedman, M.L., Myers, S.R.,
Pike, M.C., Waliszewska, A., Neubauer, J., Tandon, A.,
Schirmer, C., McDonald, G.J., et al. (2007). Multiple regions
within 8q24 independently affect risk for prostate cancer.
Nat. Genet. 39, 638–644.
52. Gudmundsson, J., Sulem, P., Manolescu, A., Amundadottir,
L.T., Gudbjartsson, D., Helgason, A., Rafnar, T., Bergthorsson,
J.T., Agnarsson, B.A., Baker, A., et al. (2007). Genome-wide as-
sociation study identiﬁes a second prostate cancer susceptibil-
ity variant at 8q24. Nat. Genet. 39, 631–637.
53. Hugot, J.P., Laurent-Puig, P., Gower-Rousseau, C., Olson, J.M.,
Lee, J.C., Beaugerie, L., Naom, I., Dupas, J.L., Van Gossum, A.,
Orholm, M., et al. (1996). Mapping of a susceptibility locus
for Crohn’s disease on chromosome 16. Nature 379,
821–823.
54. Rioux, J.D., Xavier, R.J., Taylor, K.D., Silverberg, M.S., Goyette,
P., Huett, A., Green, T., Kuballa, P., Barmada, M.M., Datta,
L.W., et al. (2007). Genome-wide association study identiﬁes
new susceptibility loci for Crohn disease and implicates au-
tophagy in disease pathogenesis. Nat. Genet. 39, 596–604.
55. Wiltshire, S., Hattersley, A.T., Hitman, G.A., Walker, M., Levy,
J.C., Sampson, M., O’Rahilly, S., Frayling, T.M., Bell, J.I.,2008
Lathrop, G.M., et al. (2001). A genomewide scan for loci
predisposing to type 2 diabetes in a U.K. population (the
Diabetes UK Warren 2 Repository): Analysis of 573 pedigrees
provides independent replication of a susceptibility locus on
chromosome 1q. Am. J. Hum. Genet. 69, 553–569.
56. Grant, S.F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R.,
Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emils-
son, V., Helgadottir, A., et al. (2006). Variant of transcription
factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes.
Nat. Genet. 38, 320–323.
57. Helgason, A., Pa´lsson, S., Thorleifsson, G., Grant, S.F., Emils-
son, V., Gunnarsdottir, S., Adeyemo, A., Chen, Y., Chen, G.,The AmReynisdottir, I., et al. (2007). Reﬁning the impact of TCF7L2
gene variants on type 2 diabetes and adaptive evolution.
Nat. Genet. 39, 218–225.
58. Lundmark, F., Duvefelt, K., Iacobaeus, E., Kockum, I., Wall-
stro¨m, E., Khademi, M., Oturai, A., Ryder, L.P., Saarela, J.,
Harbo, H.F., et al. (2007). Variation in interleukin 7 receptor
alpha chain (IL7R) inﬂuences risk of multiple sclerosis. Nat.
Genet. 39, 1108–1113.
59. Haﬂer, D.A., Compston, A., Sawcer, S., Lander, E.S., Daly, M.J.,
De Jager, P.L., de Bakker, P.I., Gabriel, S.B., Mirel, D.B., Ivinson,
A.J., et al. (2007). Risk alleles for multiple sclerosis identiﬁed
by a genomewide study. N. Engl. J. Med. 357, 851–862.erican Journal of Human Genetics 82, 1051–1063, May 2008 1063
